PMID: 32162607 Pajuelo D, et al
It's a clinically supervised program that starts with comprehensive baseline labs, pairs you with a physician who understands longevity medicine, and builds a personalized protocol that may include peptide therapy alongside other interventions, such as GLP-1 support through GLP-1 Longevity Care for those with appropriate metabolic indications, or foundational longevity support through Foundayo Pill with Ongoing Care
Tanday et al., (2022) have since described a role for Y1-R agonism in inducing periods of -cell rest that, when combined with GLP-1R agonism, proved beneficial in obesity-driven models of diabetes
Certain people pour scorn on weight-loss drugs, citing their use as cheating, or claiming that they are harmful
Nausea and vomiting tend to occur early on and often resolve within a few weeks or months
Highlights from study findings include: 751 individuals participated in the study The mean percent change in weight at week 72 was -20.2% for those taking tirzepatide and -13.7% for those taking semaglutide The most common side effects were gastrointestinal A 2025 real-world study of over 2,300 patients treated at an academic obesity clinic also showed meaningful weight loss, especially among those who stayed on therapy for at least a year